1. Loss of E-cadherin Activates EGFR-MEK/ERK Signaling, Promoting Cervical Cancer Progression. 

 Cancer Genomics Proteomics. 2025 Mar-Apr;22(2):271-284. 

2. Lugol's Solution Reduces Positive Margins and Residual Disease After the Large Loop Excision of Transformation Zone.

 J Low Genit Tract Dis. 2024 Jan 1;28(1):12-17.

3. Tetraspanin 1 promotes endometriosis leading to ovarian clear cell carcinoma.

 Mol Oncol. 2021 Apr;15(4):987-1004. 

4. The Combination of Transient Receptor Potential Vanilloid Type 1 (TRPV1) and Phosphatase and Tension Homolog (PTEN) is an Effective Prognostic Biomarker in Cervical Cancer.

 Int J Gynecol Pathol. 2021 May 1;40(3):214-223. 

5. Loss of Both USP10 and p14ARF Protein Expression Is an Independent Prognostic Biomarker for Poor Prognosis in Patients With Epithelial Ovarian Cancer. 

 Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):553-562.

6. Forkhead box protein O1 (FOXO1) and paired box gene 3 (PAX3) overexpression is associated with poor prognosis in patients with cervical cancer. 

 Int J Clin Oncol. 2019 Nov;24(11):1429-1439. 

7. Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth.

 Int J Hyperthermia. 2019;36(1):9-20. 

8. Establishment of five immortalized human ovarian surface epithelial cell lines via SV40 T antigen or HPV E6/E7 expression.

 PLoS One. 2018 Oct 8;13(10):e0205297.

9. DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis

in Endometrial Cancer. Cancers (Basel). 2018 Aug 21;10(9):279. 

10. Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian

carcinomas. Obstet Gynecol Sci. 2018 May;61(3):344-351.

11. Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.

  Gynecol Oncol. 2018 May;149(2):381-387. 

12. Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in

Patient-Derived Xenograft Models. Cancer Res Treat. 2018 Jul;50(3):956-963. 

13. API5 induces cisplatin resistance through FGFR signaling in human cancer cells.

Exp Mol Med. 2017 Sep 8;49(9):e374.

14. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.

 Yonsei Med J. 2016 May;57(3):580-7.

15. Makorin Ring Finger Protein 1 as Adjunctive Marker in Liquid-based Cervical Cytology.

 Medicine (Baltimore). 2016 Jan;95(3):e2425. 

16. Clinical significance of serum anti-human papillomavirus 16 and 18 antibodies in cervical neoplasia.

 Obstet Gynecol. 2013 Feb;121(2 Pt 1):321-329. 

17. Prevalence and seroprevalence of low-risk human papillomavirus in Korean women.

 J Korean Med Sci. 2012 Aug;27(8):922-8. 

18. Prevalence and seroprevalence of high-risk human papillomavirus infection. 

 Obstet Gynecol. 2010 Oct;116(4):932-940.

19. ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139. 

 Int J Oncol. 2010 Aug;37(2):399-412. 

20. Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. 

 Am J Obstet Gynecol. 2008 Apr;198(4):373.e1-7.